Citations

Clear

3942 citation(s) found for "To, Van".

Mitotic Inheritance of mRNA Facilitates Translational Activation of the Osteogenic‐Lineage Commitment Factor Runx2 in Progeny of Osteoblastic Cells
Varela, Nelson , Aránguiz, Alejandra, Lizama, Carlos O. , Sepúlveda, Hugo , Antonelli, Marcelo , Thaler, Roman , Moreno, Ricardo D. , Montecino, Martı́n , Stein, Gary S., Wijnen, André J. van , Galindo, Mario , van Wijnen, Andre J, van Wijnen, Andre J

Mayo Clinic

Journal of Cellular Physiology | September 7, 2015 | Volume: 231 | Issue: 5 | Pages: 1001-1014

10.1002/jcp.25188 | PMID 26381402 Get It

Epigenetic mechanisms mediate the acquisition of specialized cellular phenotypes during tissue development, maintenance and repair. When phenotype‐committed cells transit through mitosis, chromosomal condensation counteracts epigenetic activation of gene expression. Subsequent post‐mitotic re‐activation of transcription depends on epigenetic DNA and histone modifications, as well as other architecturally bound proteins that “bookmark” the genome. Osteogenic lineage commitment, differentiation and progenitor proliferation require the bone‐related runt‐related transcription factor Runx2. Here, we characterized a non‐genomic mRNA mediated mechanism by which osteoblast precursors retain their phenotype during self‐renewal. We show that osteoblasts produce maximal levels of Runx2 mRNA, but not protein, prior to mitotic cell division. Runx2 mRNA partitions symmetrically between daughter cells in a non‐chromosomal tubulin‐containing compartment. Subsequently, transcription‐independent de novo synthesis of Runx2 protein in early G1 phase results in increased functional interactions of Runx2 with a representative osteoblast‐specific target gene (osteocalcin/BGLAP2) in chromatin. Somatic transmission of Runx2 mRNAs in osteoblasts and osteosarcoma cells represents a versatile mechanism for translational rather than transcriptional induction of this principal gene regulator to maintain osteoblast phenotype identity after mitosis. J. Cell. Physiol. 231: 1001–1014, 2016. © 2015 Wiley Periodicals, Inc.
Meeting report: discussions and preliminary findings on extracellular RNA measurement methods from laboratories in the NIH Extracellular RNA Communication Consortium
Laurent, Louise C. , Abdel‐Mageed, Asim B. , Adelson, P. David , Arango, Jorge , Balaj, Leonora , Breakefield, Xandra O., Carlson, Elizabeth, Majem, Blanca , Chen, Clark C. , Cocucci, Emanuele , Danielson, Kirsty , Courtright, Amanda, Das, Saumya , Enderle, Daniel , Ezrin, Alan M., Galas, David J. , Gandhi, Roopali, Huentelman, Matthew J. , Keuren‐Jensen, Kendall Van , Kalani, Yashar, Kim, Yong , Krichevsky, Anna M. , Lai, Charles Pin‐Kuang , Lal‐Nag, Madhu , Laurent, Clara D., Leonardo, Trevor R. , Malenica, Ivana , Mondal, Debasis , Nejad, Parham, Raffaı̈, Robert L. , Rubio, Renee, Skog, Johan , Spetzler, Robert, Sun, Jie , Tanrıverdi, Kahraman , Vickers, Kasey C. , Wang, Yaoyu, Weiner, Howard L. , Yeri, Ashish, Gould, Stephen J. , Breakefield, Xandra O. , Courtright-Lim, Amanda , Yan, Irene K. , Laurent, Louise C , Carter, Bob S. , Elmageed, Zakaria Y. Abd , Ferrer, Marc , Freedman, Jane E. , Li, Feng , Patel, Tushar , Wang, Liang , Wang, Yaoyu, Wei, Zhiyun , Wong, David T.

Mayo Clinic

Journal of Extracellular Vesicles | August 28, 2015 | Volume: 4 | Issue: 1 | Pages: No page available

10.3402/jev.v4.26533 | PMID 26320937 Get It

Extracellular RNAs (exRNAs) have been identified in all tested biofluids and have been associated with a variety of extracellular vesicles, ribonucleoprotein complexes and lipoprotein complexes. Much of the interest in exRNAs lies in the fact that they may serve as signalling molecules between cells, their potential to serve as biomarkers for prediction and diagnosis of disease and the possibility that exRNAs or the extracellular particles that carry them might be used for therapeutic purposes. Among the most significant bottlenecks to progress in this field is the lack of robust and standardized methods for collection and processing of biofluids, separation of different types of exRNA‐containing particles and isolation and analysis of exRNAs. The Sample and Assay Standards Working Group of the Extracellular RNA Communication Consortium is a group of laboratories funded by the U.S. National Institutes of Health to develop such methods. In our first joint endeavour, we held a series of conference calls and in‐person meetings to survey the methods used among our members, placed them in the context of the current literature and used our findings to identify areas in which the identification of robust methodologies would promote rapid advancements in the exRNA field.
Extracellular RNAs: development as biomarkers of human disease
Das, Saumya , Freedman, Jane E. , Laurent, Louise C. , Hochberg, Fred H. , Keuren‐Jensen, Kendall Van , Huentelman, Matt , Spetzler, Robert, Arango, Jorge , Adelson, P. David , Weiner, Howard L. , Gandhi, Roopali, Putterman, Chaim , Saugstad, Julie A. , Quinn, Joseph F. , Patel, Tushar , Wong, David T. , Laurent, Louise C , Carter, Bob S. , Kalani, M. Yashar S. , Goilav, Béatrice , Saugstad, Julie A

Mayo Clinic

Journal of Extracellular Vesicles | August 28, 2015 | Volume: 4 | Issue: 1 | Pages: No page available

10.3402/jev.v4.27495 | PMID 26320940 Get It

Ten ongoing studies designed to test the possibility that extracellular RNAs may serve as biomarkers in human disease are described. These studies, funded by the NIH Common Fund Extracellular RNA Communication Program, examine diverse extracellular body fluids, including plasma, serum, urine and cerebrospinal fluid. The disorders studied include hepatic and gastric cancer, cardiovascular disease, chronic kidney disease, neurodegenerative disease, brain tumours, intracranial haemorrhage, multiple sclerosis and placental disorders. Progress to date and the plans for future studies are outlined.
Catastrophic Head-Neck Dissociation of a Modular Cementless Femoral Component
Swann, R. Presley, Webb, Jonathan E., Cass, Joseph R., Lewallen, David G. , Citters, Douglas W. Van

Mayo Clinic

JBJS Case Connector | August 26, 2015 | Volume: 5 | Issue: 3 | Pages: e71

10.2106/jbjs.cc.n.00179 | PMID 29252857 Get It

Case: We report two cases of modular head-neck junction failure involving the Stryker Accolade TMZF stem leading to sudden dissociation of the femoral head from the stem. Both patients presented with mechanical symptoms in the hip followed by pain and hip dysfunction. Disassembly of the head and deformation of the male taper were seen on preoperative radiographs. Intraoperatively, both patients had substantial metallosis with a markedly damaged taper requiring stem revision. Conclusion: We recommend regular clinical and radiographic surveillance of patients with the Stryker Accolade TMZF stem, especially those patients with pain and/or mechanical symptoms.
Volumetric MRI data correlate to disease severity in metachromatic leukodystrophy
Tillema, Jan‐Mendelt , Derks, Marloes G.M. , Pouwels, Petra J. W. , Rappard, Diane F. van, Barkhof, Frederik , Steenweg, Marjan E., Wolf, Nicole I. , Graaf, Pim de , Knaap, Marjo S. van der , Wolf, Nicole I , Barkhof, Frederik

Mayo Clinic

Annals of Clinical and Translational Neurology | August 24, 2015 | Volume: 2 | Issue: 9 | Pages: 932-940

10.1002/acn3.232 | PMID 26401514 Get It

AbstractObjectiveMetachromatic leukodystrophy (MLD) is an inherited lysosomal disorder due to a deficiency in arylsulfatase A with progressive demyelination and neurological decline. This retrospective MRI study investigated the extent of cortical involvement at time of diagnosis, and clinical correlates to both conventional and regional volumetric measures of brain involvement.Methods3D‐T1‐weighted MRI scans were used to determine cortical thickness and surface‐based cerebral cortical gray matter (GM) and cerebral white matter (WM) volume (GMV and WMV), WM lesions, thalamus, and cerebellum. MRI‐MLD severity scores were obtained from FLAIR images. Associations between clinical and imaging data were examined using correlation coefficients.ResultsTwenty patients with MLD (mean age 13.7 years, range 2–35) and 20 controls (mean age 13.9 years, range 2–40) were included. Compared with control subjects, late‐infantile, and juvenile patients (n = 14) had significantly diminished cerebral cortical GMV and thalamus volume (P < 0.05), but did not differ in WMV and cortical thickness. Adult patients (n = 6) showed significantly reduced GMV, WMV and cortical thickness (all P < 0.05). Regional analysis showed statistically significant cortical thinning in the cingulate gyrus and most pronounced thinning with age in the frontal lobe of MLD patients. Intelligence quotient (IQ) correlated with MRI‐MLD scores (r = −0.87, P < 0.001).InterpretationSignificant cerebral cortical GMV loss is already present in early stages of MLD. IQ correlates with WM severity scores and lesion volume, but not with volumetric measures. In adult presentations, there is more pronounced global atrophy with GMV and WMV loss and accelerated cortical thinning, most prominently in the cingulate gyrus and frontal lobes.
Abstract B28: Co-occupancy of AML1-ETO and N-CoR defines a dominant phenotypic signature in leukemic cells.
Trombly, Daniel J., Padmanabhan, Srivatsan , Gordon, Jonathan A. R., Lian, Jane B. , Wijnen, André J. van , Stein, Janet L. , Whitfield, Troy W. , Zaidi, Sayyed K. , Stein, Gary S. , van Wijnen, Andre J

Mayo Clinic

Clinical Cancer Research | August 21, 2015 | Volume: 21 | Issue: 17_Supplement | Pages: B28-B28

10.1158/1557-3265.hemmal14-b28 Get It

Abstract The t(8;21) chromosomal translocation produces AML1-ETO, an oncogenic fusion protein that compromises the function of AML1, a transcription factor critical for the myeloid cell differentiation. The differentiation arrest and self-renewal phenotypes of cells expressing AML1-ETO have been chiefly studied at the single gene level. In order to understand how the genome-wide occupancy of AML1-ETO and associated co-regulators contributes to the leukemic properties of Kasumi-1 cells, a model system for human t(8;21) leukemia, chromatin immunoprecipitation-sequencing (ChIP-seq) experiments were employed. Genome-wide DNA binding profiles for AML1 and AML1-ETO in Kasumi-1 cells showed that both proteins were enriched at introns and distal upstream regulatory regions, the latter implying that distal elements are likely important for target gene regulation. Importantly, A substantial fraction of AML1/AML1-ETO-p300 co-localization occurs near transcriptional start sites (TSSs) in promoter regions associated with transcriptionally active loci, as indicated by an observed enrichment of the H3K4me3 histone modification. A significant discovery of the current study is the co-localization of AML1/AML1-ETO with N-CoR on regions that are primarily distal to TSSs. Analyses of both gene expression data and gene ontology suggest that the AML1/AML1-ETO co-localization with N-CoR, more so than with p300, is associated with the leukemic phenotype of Kasumi-1 cells. De novo motif discovery reveals that PU.1 motifs are over-represented in regions co-occupied by AML1-ETO and N-CoR compared to other AML1-ETO bound regions. Our findings establish a novel and predominant AML leukemia signature characterized by occupancy of the AML1-ETO/N-CoR complex at genomic regions enriched in motifs for myeloid differentiation factors. We propose that this property is critical for maintenance of the leukemic phenotype. Citation Format: Daniel J. Trombly, Troy W. Whitfield, Srivatsan Padmanabhan, Jonathan A. Gordon, Jane B. Lian, Andre J. van Wijnen, Sayyed K. Zaidi, Janet L. Stein, Gary S. Stein. Co-occupancy of AML1-ETO and N-CoR defines a dominant phenotypic signature in leukemic cells. [abstract]. In: Proceedings of the AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; Sep 20-23, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(17 Suppl):Abstract nr B28.
van der Waals force-induced loading of proangiogenic nanoparticles on microbubbles for enhanced neovascularization
Chen, Jinrong , Lee, Min Kyung , Qin, Ellen C., Kong, Hyunjoon , Misra, Sanjay , Lee, Min Kyung, Misra, Sanjay, Kong, Hyunjoon , Misra, Sanjay

Mayo Clinic

Nanoscale | August 20, 2015 | Volume: 7 | Issue: 40 | Pages: 17139-17147

10.1039/c5nr03399c | PMID 26422546 Get It

Nanoparticles emerged as carriers of promising diagnostic and therapeutic molecules due to their unique size, injectability, and potential to sustainably release molecular cargos.
Pregnant patients' risk perception of prenatal test results with uncertain fetal clinical significance: ultrasound versus advanced genetic testing
Richards, Elliott G. , Sangi‐Haghpeykar, Haleh , Veyver, Ignatia B. Van den , Fruhman, Gary , McGuire, Amy L

Mayo Clinic

Prenatal Diagnosis | August 19, 2015 | Volume: 35 | Issue: 12 | Pages: 1213-1217

10.1002/pd.4680 | PMID 26287960 Get It

AbstractObjectiveA common concern of utilizing prenatal advanced genetic testing is that a result of uncertain clinical significance will increase patient anxiety. However, prenatal ultrasound may also yield findings of uncertain significance, such as ‘soft markers’ for fetal aneuploidy, or findings with variable prognosis, such as mild ventriculomegaly. In this study we compared risk perception following uncertain test results from each modality.MethodsA single survey with repeated measures design was administered to 133 pregnant women. It included ‘intolerance of uncertainty’ questions, two hypothetical scenarios involving prenatal ultrasound or advanced genetic testing, and response questions. The primary outcome was risk perception score.ResultsRisk perception did not vary significantly between ultrasound and genetic scenarios (p = 0.17). The genetic scenario scored a higher accuracy (p = 0.04) but lower sense of empowerment (p = 0.01). Furthermore, patients were more likely to seek additional testing after an ultrasound than after genetic testing (p = 0.05). There were no differences in other secondary outcomes including perception of life‐altering consequences and hypothetical worry, anxiety, confusion, or medical care decisions.ConclusionsOur data suggest that uncertain findings on prenatal genetic testing do not elicit a higher perception of risk or anxiety when compared to ultrasound findings of comparable uncertainty. © 2015 John Wiley & Sons, Ltd.
DNAJC13 p.Asn855Ser mutation screening in Parkinson's disease and pathologically confirmed Lewy body disease patients
Lorenzo‐Betancor, Oswaldo , Ogaki, Kotaro, Soto‐Ortolaza, Alexandra I., Walton, Ronald L., Strongosky, Audrey , Gerpen, Jay A. van, Uitti, Ryan J. , McLean, Pamela J. , Springer, Wolfdieter , Siuda, Joanna , Opala, Grzegorz, Krygowska‐Wajs, Anna , Barcikowska, Maria , McCarthy, A., Lynch, Timothy , Puschmann, Andreas , Rektorová, Irena , Sanotsky, Yanosh, Vilariño‐Güell, Carles , Farrer, Matthew J. , Ferman, Tanis J. , Petersen, Ronald C. , Parisi, Joseph E., Graff‐Radford, Neill R. , Ross, Owen A. , Soto‐Beasley, Alexandra I. , Labbé, Catherine , Siuda, Joanna S. , Czyźewski, K , Boeve, Bradley F. , Dickson, Dennis W. , Wszołek, Zbigniew K. , Ross, Owen A , Puschmann, Andreas , Springer, Wolfdieter , Ferman, Tanis J , Rektorova, Irena , Beasley, Alexandra I , McLean, Pamela J

Mayo Clinic

European Journal of Neurology | August 17, 2015 | Volume: 22 | Issue: 9 | Pages: 1323-1325

10.1111/ene.12770 | PMID 26278106 Get It

BackgroundRecently, a novel mutation in exon 24 of DNAJC13 gene (p.Asn855Ser, rs387907571) has been reported to cause autosomal dominant Parkinson's disease (PD) in a multi‐incident Mennonite family.MethodsIn the present study the mutation containing exon of the DNAJC13 gene has been sequenced in a Caucasian series consisting of 1938 patients with clinical PD and 838 with pathologically diagnosed Lewy body disease (LBD).ResultsOur sequence analysis did not identify any coding variants in exon 24 of DNAJC13. Two previously described variants in intron 23 (rs200204728 and rs2369796) were observed.ConclusionOur results indicate that the region surrounding the DNAJC13 p.Asn855Ser substitution is highly conserved and mutations in this exon are not a common cause of PD or LBD among Caucasian populations.
Anesthesia and Poliomyelitis: A Matched Cohort Study
Alstine, Luke W. Van, Gunn, Paul W., Schroeder, Darrell R. , Hanson, Andrew C. , Sorenson, Eric J. , Martin, David P. , Van Alstine, Luke W, Schroeder, Darrell

Mayo Clinic

Anesthesia & Analgesia | August 14, 2015 | Volume: 122 | Issue: 6 | Pages: 1894-1900

10.1213/ane.0000000000000924 | PMID 26273744 Get It

BACKGROUND: Poliomyelitis is a viral infectious disease caused by 1 of the 3 strains of poliovirus. The World Health Organization launched an eradication campaign in 1988. Although the number of cases of poliomyelitis has drastically declined, eradication has not yet been achieved, and there are a substantial number of survivors of the disease. Survivors of poliomyelitis present a unique set of challenges to the anesthesiologist. The scientific literature regarding the anesthetic management of survivors of poliomyelitis, however, is limited and primarily experiential in nature. Using a retrospective, matched cohort study, we sought to more precisely characterize the anesthetic implications of poliomyelitis and to determine what risks, if any, may be present for patients with a history of the disease. METHODS: Using the Mayo Clinic Life Sciences System Data Discovery and Query Builder, study subjects were identified as those with a history of paralytic poliomyelitis who had undergone major surgery at Mayo Clinic Rochester between 2005 and 2009. For each case, 2 sex- and age-matched controls that underwent the same surgical procedure during the study period were randomly selected from a pool of possible controls. Medical records were manually interrogated with respect to demographic variables, comorbid conditions, operative and anesthetic course, and postoperative course. RESULTS: We analyzed 100 cases with 2:1 matched controls and found that the peri- and postoperative courses were very similar for both groups of patients. Pain scores, postanesthesia care unit admission, length of postanesthesia care unit stay, intensive care unit admission, length of intensive care unit stay, and initial extubation location were not significantly different between the 2 groups. Looking at pulmonary complications in our primary outcome, there was no significant difference between the 2 groups (17% vs 14% for polio versus control, respectively; conditional logistic regression odds ratio = 1.5; 95% confidence interval, 0.7–3.3; P = 0.33). In addition, no difference was noted in those requiring a code or rapid response team intervention (4% vs 3% for polio versus control; P = 0.46) and the 30-day mortality rate was also not significantly different, with 2% of polio patients dying compared with 3% of controls ( P = 0.79). The analysis of the primary outcome was repeated for the subset of patients with a history of poliomyelitis who had persistent neurologic deficits preoperatively ( n = 36) and their matched controls ( n = 72). In this subset analysis, there were 4 (11%) polio patients and 8 (11%) control patients who experienced pulmonary complications (conditional logistic regression odds ratio = 1.00; 95% confidence interval, 0.27–3.72; P = 1.00). The percentage of patients experiencing specific pulmonary complications of interest was similar between groups (postoperative mechanical ventilation: 6% vs 8% for polio and control patients, respectively; prolonged mechanical ventilation: 0% vs 1%; reintubation: 8% vs 4%; pulmonary infection: 6% vs 6%; and aspiration: 0% vs 1%). CONCLUSIONS: This study suggests that patients with a history of poliomyelitis do not seem to have an increased risk of pulmonary complications in the perioperative period. However, an odds ratio as great as 3.3-fold may be present.